[1] Danan G, Benichou C. Causality assessment of adverse reactions to drugs-Ⅰ. A novel method based on the conclusions of international consensus meetings: application to drug-induced liver injuries. J Clin Epidemiol, 1993, 46: 1323-1330. [2] Navarro VJ, Senior JR. Drug-related hepatotoxicity.N Eng J Med, 2006, 354: 731-739. [3] 张曙云,黄龙天,俞小忠,等.肝功能异常与代谢综合征的关系. 中国慢性病预防与控制, 2008,16:393-395. [4] Baig NA, Herrine SK, Rubin R. Liver disease and diabetes mellitus. Clin Lab Med, 2001, 21: 193-207. [5] 刘会领,罗雁,梅玫,等.免疫机制在药物性肝损伤中的作用研究进展.实用医学杂志, 2012, 28: 852-853. [6] 中华医学会结核病学分会,《中华结核和呼吸杂志》编辑委员会. 抗结核药所致药物性肝损伤诊断与处理专家建议.中华结核和呼吸杂志,2013,36: 732-736. [7] 刘玉兰,王晶桐.老年人药物性肝损害的诊治.中华老年医学杂志, 2009, 28: 274-275. [8] Cotreau MM, von Moltke LL, Greenblatt DJ.The influence of age and sex on the clearance of cytochrome P450 3A substrates.Clin Pharmacokinet, 2005, 44: 33-60. [9] Lewis JH, Mortensen ME, Zweig S. Efficacy and safety of highdose pravastatin in hypercholesterolemic patients with wellcompensated chronic liver disease: results of a prospective,randomized, double-blind, placebo-controlled, multicentertrial.Hepatology, 2007, 46: 1453-1463. [10] Russmann S, Jetter A, Kullak-Ublick GA.Pharmacogenetics of drug-induced liver injury.Hepatology,2010,52:748-761. |